Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21062027 | 0.90 | CYP2C9 (0.39) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21062029 | 0.83 | KDM4E (0.36) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21061848 | 0.82 | ALDH1A1 (0.40) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21062045 | 0.81 | SMN1; SMN2 (0.42) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21096506 | 0.78 | CYP2C9 (0.47) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17901838 | 0.76 | ALDH1A1 (0.50) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14859368 | 0.75 | CYP2C9 (0.43) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| Potassium Ion SCHEMBL14859369 | 0.75 | CYP2C9 (0.43) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| Potassium SCHEMBL14859370 | 0.75 | CYP2C9 (0.43) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21074850 | 0.74 | NPC1 (0.49) | CYP2C9CYP2C19NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | CYP2C9 551/4885CYP2C19 270/4885NPC1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.